| Literature DB >> 27051526 |
Ning Lu1, Fangyu Lin1, Zhu Huang1, Qin He1, Wei Han1.
Abstract
Purpose. To evaluate the corneal aberration changes in dry eye patients after treatment with artificial eye drops. Methods. Thirty mild to moderate dry eye patients treated with artificial eye drops and twenty comparable dry eye patients were recruited as controls. Anterior corneal aberrations over 3 mm and 5 mm analytical zones including total, 3rd to 5th high order aberrations (HOAs), spherical aberration (SA), and vertical (V-coma) and horizontal coma (H-coma) obtained from corneal topography data at baseline and 2 weeks after treatment were evaluated. Results. For 3 mm zone, trefoils, V-coma, H-coma terms, and 3rd and 5th HOAs were significantly decreased (p < 0.05) in the treatment group. For 5 mm zone, instillation of eye drops reduced H-coma, SA terms, 3rd to 5th orders, and total HOAs all showed a significant decrease (p < 0.05). The root mean square analysis of the Zernike terms also showed similar statistical results. For control group, all individual terms and total HOAs did not have significant changes over 3 mm and 5 mm zones (p > 0.05). Conclusions. Treatment with artificial eye drops can effectively improve the corneal optical quality of dry eye patients by ameliorating the HOAs of anterior corneal surface.Entities:
Year: 2016 PMID: 27051526 PMCID: PMC4808656 DOI: 10.1155/2016/1342056
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Clinical data analysis for the dry eye patients at baseline and two weeks after treatment.
| Treatment group ( | Control group ( |
| |||||
|---|---|---|---|---|---|---|---|
| Baseline | Two weeks |
| Baseline | Two weeks |
| ||
| Age (year) | 31.03 ± 4.73 (23–39) | — | 29.00 ± 5.30 (21–38) | — | >0.05 | ||
| Male/female | 14/16 | — | 12/10 | — | >0.05 | ||
| BCVA (LogMAR) | 0.14 ± 0.09 | 0.10 ± 0.05 | 0.03 | 0.12 ± 0.09 | 0.11 ± 0.07 | >0.05 | >0.05 |
| SE (diopter)# | −1.59 ± 1.16 (−6.25–+ 0.50) | — | −1.31 ± 1.56 (−5.75–+1.00) | — | >0.05 | ||
| TBUT (s) | 4.93 ± 1.31 | 6.27 ± 1.20 | <0.01 | 4.95 ± 1.13 | 5.18 ± 1.05 | >0.05 | <0.01 |
| Schirmer I score (mm) | 11.80 ± 1.77 | 12.10 ± 1.42 | >0.05 | 11.14 ± 1.73 | 11.36 ± 1.56 | >0.05 | >0.05 |
| Fluorescein stain positive (eye)§ | 18 (60%) | 5 (16.7%) | <0.01 | 12 (54.55%) | 13 (57%) | >0.05 | <0.01 |
| Eye dryness /burn/foreign body sensation (eye)§ | 25 (83.3%) | 11 (36.7%) | <0.01 | 18 (81.8%) | 19 (86.4%) | >0.05 | <0.01 |
| Vision disturbance (blur/discomfort/night vision) (eye)§ | 21 (70%) | 9 (30%) | <0.01 | 15 (68.2%) | 16 (72.8%) | >0.05 | <0.01 |
SE denotes spherical equivalence, which was calculated as sphere diopters plus half-cylinder diopters. SE of the right eyes for each subject was used for analysis.
§The numbers for these tests denote the number of eyes showing positive results and the percentage in parenthesis denotes the rate of positive results.
p indicates the significant level of t-test within treatment or control groups between baseline and two weeks after treatment.
p′ indicates the significant level of t-test between treatment and control groups after two weeks.
Figure 1Corneal topography image of one patient receiving treatment (axial power map).
Figure 2Corneal wavefront aberration contour plots of one patient receiving treatment. The patterns of (a) denote the results before treatment, while those of (b) denote the results after treatment.
Figure 3The PSF image of one patient receiving treatment with artificial tear drops. The patterns of (a) denote the results before treatment, while those of (b) denote the results after treatment.
Comparison of 3 mm and 5 mm zones Zernike terms of 3rd and 4th HOAs between baseline and 2 weeks after treatment.
| 3 mm zone | 5 mm zone | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment group ( | Control group ( | Treatment group ( | Control group ( | |||||
| Baseline | 2 weeks | Baseline | 2 weeks | Baseline | 2 weeks | Baseline | 2 weeks | |
|
| −0.0351 ± 0.0729 | 0.0052 ± 0.0411 | −0.0044 ± 0.0154 | 0.0030 ± 0.0209 | −0.0259 ± 0.1407 | 0.0189 ± 0.0908 | −0.0159 ± 0.0595 | −0.0038 ± 0.0613 |
|
| 0.0192 ± 0.0458 | −0.0181 ± 0.0454 | −0.0101 ± 0.0353 | −0.0095 ± 0.0293 | −0.0018 ± 0.1121 | −0.0453 ± 0.1301 | −0.0321 ± 0.1487 | −0.0214 ± 0.1165 |
|
| 0.0145 ± 0.0289 | 0.0032 ± 0.0215 | −0.0099 ± 0.0187 | −0.0069 ± 0.0200 | 0.0181 ± 0.0907 | −0.0081 ± 0.0919 | −0.0272 ± 0.0805 | −0.0228 ± 0.0809 |
|
| −0.0176 ± 0.0356 | 0.0128 ± 0.0373 | −0.0022 ± 0.0094 | 0.0018 ± 0.0132 | −0.0249 ± 0.0987 | 0.0316 ± 0.0872 | −0.0190 ± 0.0384 | −0.0076 ± 0.0534 |
|
| −0.0025 ± 0.0176 | −0.0023 ± 0.0160 | 0.0034 ± 0.0086 | 0.0015 ± 0.0087 | 0.0014 ± 0.0607 | −0.0117 ± 0.0264 | 0.0176 ± 0.0363 | 0.0142 ± 0.0422 |
| Z4 −2 | −0.0038 ± 0.0051 | 0.0054 ± 0.0074 | 0.0002 ± 0.0051 | 0.0005 ± 0.0069 | 0.0020 ± 0.0237 | −0.0018 ± 0.0122 | −0.0064 ± 0.0227 | −0.0061 ± 0.0311 |
|
| 0.0186 ± 0.0142 | 0.0180 ± 0.0184 | 0.0126 ± 0.0069 | 0.0089 ± 0.0121 | 0.1270 ± 0.0442 | 0.1111 ± 0.0575 | 0.1356 ± 0.0499 | 0.1231 ± 0.0469 |
|
| 0.0042 ± 0.0171 | −0.0072 ± 0.0217 | −0.0044 ± 0.0107 | −0.0036 ± 0.0103 | 0.0031 ± 0.0337 | −0.0013 ± 0.0295 | −0.0151 ± 0.0376 | −0.0183 ± 0.0457 |
|
| −0.0066 ± 0.0200 | 0.0034 ± 0.0242 | −0.0002 ± 0.0120 | 0.0009 ± 0.0124 | −0.0080 ± 0.0611 | −0.0077 ± 0.0624 | −0.0105 ± 0.0385 | 0.0009 ± 0.0519 |
p < 0.05, p < 0.01 between baseline and two weeks after treatment.
Comparison of 3 mm and 5 mm zones RMS of Zernike terms of 3rd and 4th HOAs between baseline and 2 weeks after treatment.
| 3 mm zone | 5 mm zone | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment group ( | Control group ( | Treatment group ( | Control group ( | |||||
| Baseline | 2 weeks | Baseline | 2 weeks | Baseline | 2 weeks | Baseline | 2 weeks | |
|
| 0.0479 ± 0.0349 | 0.0280 ± 0.0301 | 0.0213 ± 0.0232 | 0.0233 ± 0.0300 | 0.1135 ± 0.0846 | 0.0703 ± 0.0566 | 0.0296 ± 0.0367 | 0.0308 ± 0.0553 |
|
| 0.0342 ± 0.0355 | 0.0353 ± 0.0333 | 0.0271 ± 0.0533 | −0.0295 ± 0.0611 | 0.0918 ± 0.0620 | 0.1099 ± 0.0809 | 0.0401 ± 0.0882 | 0.0351 ± 0.0912 |
|
| 0.0239 ± 0.0214 | 0.0150 ± 0.0155 | 0.0175 ± 0.0198 | −0.0159 ± 0.0261 | 0.0743 ± 0.0534 | 0.0669 ± 0.0623 | 0.0588 ± 0.0952 | 0.0600 ± 0.0799 |
|
| 0.0286 ± 0.0272 | 0.0399 ± 0.0121 | 0.0222 ± 0.0154 | 0.0199 ± 0.0232 | 0.0765 ± 0.0657 | 0.0786 ± 0.0473 | 0.0377 ± 0.0442 | 0.0426 ± 0.0912 |
|
| 0.0133 ± 0.0114 | 0.0115 ± 0.01116 | 0.0194 ± 0.0118 | 0.0155 ± 0.0287 | 0.0496 ± 0.0338 | 0.0227 ± 0.0175 | 0.0386 ± 0.0533 | 0.0440 ± 0.0482 |
|
| 0.0050 ± 0.0032 | 0.0070 ± 0.0028 | 0.0090 ± 0.0066 | 0.0083 ± 0.0092 | 0.0166 ± 0.0167 | 0.0090 ± 0.0083 | 0.0201 ± 0.0337 | 0.0241 ± 0.0551 |
|
| 0.0198 ± 0.0124 | 0.0180 ± 0.0184 | 0.0168 ± 0.0175 | 0.0197 ± 0.0221 | 0.1270 ± 0.0441 | 0.1111 ± 0.0575 | 0.1356 ± 0.0499 | 0.1231 ± 0.0469 |
|
| 0.0136 ± 0.0108 | 0.0146 ± 0.0174 | 0.0115 ± 0.0093 | 0.0126 ± 0.0103 | 0.0229 ± 0.0245 | 0.0235 ± 0.0173 | 0.0281 ± 0.0456 | 0.0253 ± 0.0537 |
|
| 0.0176 ± 0.01115 | 0.0188 ± 0.0153 | 0.0059 ± 0.0092 | 0.0069 ± 0.0167 | 0.0498 ± 0.0351 | 0.0483 ± 0.0393 | 0.0405 ± 0.0523 | 0.0389 ± 0.0605 |
p < 0.05, p < 0.01 between baseline and two weeks after treatment.
Figure 4Zernike terms in treatment group. Vertical coma and horizontal coma decreased significantly at a 3 mm zone. Vertical coma, horizontal coma, and SA had significant mathematical decrease at 5 mm zone.
Figure 5Rangeability of HOAs (baseline minus 2 weeks) for the treatment and control groups. A positive value of RMS rangeability indicates a decreasing of HOAs amplitude after treatment, and vice versa. For 3 mm zone, the 3rd and 5th HOAs decreased significantly after two weeks of artificial tears eye drops treatment. For 5 mm zone, the 3rd, 4th, 5th, and total HOAs all showed a significant decrease after 2 weeks of treatment.